Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation

British Journal of Cancer

Volumn 96, Issue 9, 2007, Pages 1343-1347

  Correale, P ^a   Sciandivasci, A ^a   Intrivici, C ^a   Pascucci, A ^a   Del Vecchio, M T ^a   Marsili, S ^a   Savelli, V ^a   Voltolini, L ^a   Di Bisceglie, M ^a   Guarnieri, A ^a   Gotti, G ^a   Francini, G ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Chemotherapy; Hormonal manipulation; Neuroendocrine tumours

Indexed keywords

ANGIOPEPTIN; ANTIEMETIC AGENT; CISPLATIN; CORTICOSTEROID; CREATININE; ETOPOSIDE; GASTROINTESTINAL AGENT; GROWTH FACTOR; MANNITOL; SOMATOSTATIN DERIVATIVE;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CELL DIFFERENTIATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE TUMOR; FEBRILE NEUTROPENIA; FEMALE; HEART ARRHYTHMIA; HISTOLOGY; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; INFECTION; INTESTINE CANCER; LIVER METASTASIS; LUNG CANCER; MALAISE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OLIGURIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RESPIRATORY DISTRESS; SIDE EFFECT; SLOW RELEASE FORMULATION; SURVIVAL TIME; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; ENDOCRINE GLAND NEOPLASMS; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; SOMATOSTATIN;

EID: 34247575330     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603734     Document Type: Article

References (44)

1. Arabi Y, Al Knawy B, Barkun AN, Bardou M (2006) Pro/con debate: octreotide has an important role in the treatment of gastrointestinal bleeding of unknown origin? Crit Care 10(4): 218
2. Bajetta E, Bichisao E, Artale S, Celio L, Ferrari L, Di Bartolomeo M, Zilembo N, Stani SC, Buzzoni R (2000) New clinical trials for the treatment of neuroendocrine tumors. Q J Nucl Med Mar 44(1): 96-101
3. Bajetta E, Catena L, Procopio G, Bichisao E, Ferrari L, Della Torre S, De Dosso S, Iacobelli S, Buzzoni R, Mariani L, Rosai J (2005) Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment? Ann Oncol 16(8): 1374-380
4. Bajetta E, Procopio G, Ferrari L, Catena L, Del Vecchio M, Bombardieri E (2003) Update on the treatment of neuroendocrine tumors. Exp Rev Antican Ther 3(5): 631-642
5. Bajetta E, Rimassa L, Carnaghi C, Seregni E, Ferrari L, Di Bartolomeo M, Regalia E, Cassata A, Procopio G, Mariani L (1998) 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 83(2): 372-378
6. Bishop AE (2005) Pulmonary epithelial stem cells. Cell Prolif 37(1): 89-96
7. Buchanan KD, Johnston CF, O'Hare MM, Ardill JE, Shaw C, Collins JS, Watson RG, Atkinson AB, Hadden DR, Kennedy TL (1986) Neuroendocrine tumors. Am J Med 81: 14-22
8. Correale P, Caraglia M, Pepe S, Ricciardi B, Barile C, Montagnani S, Pacelli R, Bianco AR, Tagliaferri P (1994) Phorbol 12 Myristate 13-Acetate (PMA) induces neuroendocrine-like differentiation and reverses doxorubicin resistance of human colon carcinoma cells in vitro. Int J Oncol 4: 423-427
9. De Lellis RA (2001) The neuroendocrine system and its tumors: an overview. Am J Clin Pathol 115: S5
10. Di Bartolomeo M, Bajetta E, Bochicchio AM, Carnaghi C, Somma L, Mazzaferro V, Visini M, Gebbia V, Tumolo S, Ballatore P (1995) A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group Ann Oncol 6(1): 77-79
11. Dierdorf SF (2003) Carcinoid tumor and carcinoid syndrome. Curr Opin Anaesthesiol 16(3): 343-347
12. Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B, International Lanreotide and Interferon alpha Study Group (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21: 2689
13. Fenoglio-Preiser CM (2001) Gastrointestinal neuroendocrine/ neuroectodermal tumors. Am J Clin Pathol 115: S79
14. Gordon PV, Paxton JB, Fox NS (2005) Free in PMC A methodology for distinguishing divergent cell fates within a common progenitor population: adenoma- and neuroendocrine-like cells are confounders of rat ileal epithelial cell (IEC-18) culture. BMC Cell Biol 6(1): 2
15. Greco FA, Hainsworth JD (2005) Cancer of unknown primary site. In: De Vita VJ, Hellman S, Rosemberg VII SA (eds) Cancer Principle and Practice of Oncology, pp 2213-2236. Lippincott Williams and Wilkins: Philadelphia
16. Hainsworth JD, Spigel DR, Litchy S, Greco FA (2006) Pase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Peral Cancer Research Network Study. J Clin Oncol 24(22): 3548-3554
17. Hansson J, Abrahamsson PA (2003) Neuroendocrine differentiation in prostatic carcinoma. Scand J Urol Nephrol Suppl 212: 28-36
18. Hintze J (2004) NCSS and PASSS Number Cruncher Statistical Systems Kaysville, Utah www.ncss.com
19. Jensen RT (1997) Peptide therapy. Recent advances in the use of somatostatin and other peptide receptor agonists and antagonists. In: Lewis JH, Dubois A (eds) Current clinical topics in gastrointestinal pharmacology,pp 144. Blackwell Science: Malden, MA
20. Jensen RT, Doherty GM (2001) Carcinoid tumors and the carcinoid syndrome. In: DeVita Jr VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology, 6th edn, pp 1813. Lippincott Williams & Wilkins: Philadelphia
21. Jensen RT, Doherty GM (2005) Cancer of the Endocrine System: Carcinoid tumors and the carcinoid syndrome. In: De Vita VJ, Hellman S, Rosemberg VII SA (eds) Cancer Principle and Practice of Oncology, pp 1559-1571. Lippincott Williams and Wilkins: Philadelphia
22. Kumar M, Liu ZR, Thapa L, Qin RY (2004) Anti-angiogenic effects of somatostatin receptor subtype 2 on human pancreatic cancer xenografts. Carcinogenesis 25(11): 2075-2081
23. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG (1986) Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 315(11): 663-666
24. Kvols LK, Woltering EA (2006) Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. Anticancer Drugs 17(6): 601-608
25. Lamberts SWJ (1999) History of Development of Somatostatin Analogues. BristolOctreotide Decade Eds Bioscientifica Ltd: Bristo, pp 3-7
26. Langley K (1994) The neuroendocrine concept today. Ann NY Acad Sci 733: 1-17
27. Li M, Fisher WE, Kim HJ, Wang X, Brunicardi CF, Chen C, Yao Q (2005) Somatostatin, somatostatin receptors, and pancreatic cancer. World J Surg 29(3): 293-296
28. Long RM, Morrissey C, Fitzpatrick JM, Watson RW (2005) Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. Clin Sci (London) 108(1): 1-11
29. Low MJ (2004) Clinical endocrinology and metabolism. The somatostatin neuroendocrine system: physiology and clinical relevance in gastrointestinal and pancreatic disorders. Best Pract Res Clin Endocrinol Metab 18(4): 607-622
30. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, Rougier P (1999) Treatment of poorly differentiated neuroendocrine tumors with etoposide and cisplatin. Br J Cancer 81: 1351-1355
31. Mitry E, Rougier P (2001) The treatment of undifferentiated neuroendocrine tumors. Crit Rev Oncol Hematol 37(1): 47-51
32. Moertel CG (1987) An odyssey in the land of small tumors. J Clin Oncol 5: 1503-1522
33. Moertel CG, Kvols LK, O'Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68(2): 227-232
34. Nicholson SA, Ryan MR (2000) A review of cytologic findings in neuroendocrine carcinomas including carcinoid tumors with histologic correlation. Cancer 90: 148-161
35. Oberg K (2002) Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment. Curr Opin Oncol 14: 38-45
36. Patel YC (1997) Molecular Pharmacology of somatostatin receptor subtypes. J Endocr Invest 20: 348-367
37. Polak JM (1993) Diagnostic histopatology of neuroendocrine tumors. Churchill Livingstone: Edinburgh, pp 1-39
38. Rougier P, Ducreux M (1999) Systemic chemotherapy of advanced digestive neuroendocrine tumours. Ital J Gastroenterol Hepatol 31: S202
39. Ruan W, Fahlbusch F, Clemmons DR, Monaco ME, Walden PD, Silva AP, Schmid HA, Kleinberg DL (2006) SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor3? Mol Endocrinol 20(2): 426-436
40. Sauer CG, Roemer A, Grobholz R (2006) Genetic analysis of neuroendocrine tumor cells in prostatic carcinoma. Prostate 66(3): 227-234
41. Singhal SS, Wickramarachchi D, Singhal J, Yadav S, Awasthi YC, Awasthi S (2006) Determinants of differential doxorubicin sensitivity between SCLC and NSCLC. FEBS Lett 580(9): 2258-2264
42. True L (2004) Why we must better understand neuroendocrine differentiation in prostate cancer. J Urol 171(1): 443-444
43. Wiedenmann B, Huttner W (1989) Synaptophysin and chromogranin? secretogranines: Widespread constituent of distinct types of neuroendocrine vescicles and new tool s in tumor diagnoses. Virch Arch B Cell Pathol 58: 95-121
44. Wright ME, Tsai MJ, Aebersold R (2003) Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 17(9): 1726-1737